Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.40 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15619125 | 0.77 | MTNR1A (0.43) | MTNR1AMTNR1BL3MBTL1BRD4GABRA5 | |
| SCHEMBL404007 | 0.75 | TDP2 (0.42) | BRD4 | |
| SCHEMBL12318344 | 0.75 | MTNR1A (0.48) | MTNR1AMTNR1BL3MBTL1ALDH1A1 | |
| Nitrogen SCHEMBL28021202 | 0.72 | MTNR1A (0.46) | MTNR1AMTNR1BL3MBTL1ALDH1A1 | |
| SCHEMBL9863289 | 0.71 | MTNR1A (0.52) | MTNR1AMTNR1BPTPRCL3MBTL1KDM4E | |
| SCHEMBL10191572 | 0.71 | GPBAR1 (0.44) | RXRARXRBRXRGGPBAR1KDM4E | |
| SCHEMBL15619422 | 0.71 | MTNR1A (0.37) | MTNR1AMTNR1BL3MBTL1GABRA5KDM4E | |
| SCHEMBL27962601 | 0.69 | LMNA (0.35) | L3MBTL1RXRARXRBRXRGNR4A2 | |
| SCHEMBL405942 | 0.69 | TSHR (0.50) | L3MBTL1GPBAR1KDM4EALDH1A1 | |
| SCHEMBL402940 | 0.68 | MCL1 (0.49) | RXRARXRBRXRGGPBAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | MTNR1A 3405/4885MTNR1B 3436/4885PTPRC 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.